FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013?
about
Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevanceGenomics-based Approach and Prognostic Stratification Significance of Gene Mutations in Intermediate-risk Acute Myeloid LeukemiaDrugging the unfolded protein response in acute leukemiasRUNX1 truncation resulting from a cryptic and novel t(6;21)(q25;q22) chromosome translocation in acute myeloid leukemia: A case reportNovel ZEB2-BCL11B Fusion Gene Identified by RNA-Sequencing in Acute Myeloid Leukemia with t(2;14)(q22;q32)Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemiaSorafenib is tolerable and improves clinical outcomes in patients with FLT3-ITD acute myeloid leukemia prior to stem cell transplant and after relapse post-transplantAdvances in treating acute myeloid leukemia.Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia.DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategiesA regimen combining the Wee1 inhibitor AZD1775 with HDAC inhibitors targets human acute myeloid leukemia cells harboring various genetic mutations.Rational Combinations of Targeted Agents in AMLClinical evaluation of panel testing by next-generation sequencing (NGS) for gene mutations in myeloid neoplasms.Quantitative fragment analysis of FLT3-ITD efficiently identifying poor prognostic group with high mutant allele burden or long ITD length.Microenvironmental hypoxia regulates FLT3 expression and biology in AML.Revealing very small FLT3 ITD mutated clones by ultra-deep sequencing analysis has important clinical implications in AML patients.Acute myeloid leukemia in the era of precision medicine: recent advances in diagnostic classification and risk stratification.How I treat FLT3-mutated AML.A targeted next-generation sequencing in the molecular risk stratification of adult acute myeloid leukemia: implications for clinical practice.FLT3 inhibitors in AML: are we there yet?Quizartinib for the treatment of FLT3/ITD acute myeloid leukemia.Minimal residual disease in acute myeloid leukemia--current status and future perspectives.Novel drug therapies in myeloid leukemia.Management of Relapsed/Refractory Acute Myeloid Leukemia in the Elderly: Current Strategies and Developments.FLT3 dancing on the stem cell.Integration of Hedgehog and mutant FLT3 signaling in myeloid leukemia.Spontaneous Remission in an Older Patient with Relapsed FLT3 ITD Mutant AML.Molecular landscape in acute myeloid leukemia: where do we stand in 2016Harnessing the power of proteomics for identification of oncogenic, druggable signalling pathways in cancer.Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis.Impact of Notch disruption on myeloid developmentPhase 1 dose escalation trial of ilorasertib, a dual Aurora/VEGF receptor kinase inhibitor, in patients with hematologic malignancies.A Pyrazolo[3,4-d]pyrimidine Compound Reduces Cell Viability and Induces Apoptosis in Different Hematological Malignancies.Genetic alterations of m6A regulators predict poorer survival in acute myeloid leukemia.Acute Myeloid Leukemia-Genetic Alterations and Their Clinical Prognosis.Tyrosine kinase inhibition increases the cell surface localization of FLT3-ITD and enhances FLT3-directed immunotherapy of acute myeloid leukemia.FMS-Like Tyrosine Kinase 3 (FLT3) and Nucleophosmin 1 (NPM1) in Iranian Adult Acute Myeloid Leukemia Patients with Normal Karyotypes: Mutation Status and Clinical and Laboratory Characteristics.Prevalence and Clinical Significance of FLT3 and NPM1 Mutations in Acute Myeloid Leukaemia Patients of Assam, India.Glutaminolysis is a metabolic dependency in FLT3ITD acute myeloid leukemia unmasked by FLT3 tyrosine kinase inhibition.
P2860
Q26776393-D1E54D62-C464-40A1-ABE0-3828113A7009Q26796514-66377005-C29B-48DD-BA90-3DFC47668AE0Q26801114-D98D0238-1891-49FB-9C82-BBC35F6FF59FQ28597831-FA280E85-74BF-4E6F-8EA7-8743EB3CE94AQ28646898-E452A786-9739-4547-9FBF-806F30F30445Q33442949-88ABE82E-E8FE-44C0-9259-731634B4882CQ33943277-C065AC9E-57A1-4C74-A496-E30CEA87F450Q34088370-5B51B982-618C-43F4-ABD0-9E5A5B117BECQ34312351-593F2ECA-C72B-4C57-BD21-DE891B535561Q34620695-B292F725-2A42-42B9-BADF-E8AE1015FBECQ34661033-C08778A0-A7E4-413C-AE71-CEF90928DC0EQ35287823-564E4ECA-A7CA-47F1-94CC-02CC81E2E365Q35750491-834FC3FC-878D-4A65-8824-CA64FDCCC8B6Q35900361-126809A9-285C-4DBB-859F-A3293A79345FQ36022521-3FAD441F-03DE-4D8C-A651-6034EA5598FEQ36329436-E955330C-740B-4D52-A2B7-0110153E5DF0Q36544560-A9B795B3-CECA-4103-89E7-E39EB286BCADQ36849666-C4FEAF6C-86E7-4BA9-A0CA-97B1B3ED71B7Q37623389-1D80A706-C73E-4762-9C85-D6E95D34D53FQ37648114-F77CBE0E-D03F-4DBF-BDA8-88672D0FE97FQ38200564-6395B8F8-1693-430C-8421-F03BEC550136Q38241988-18E1FB22-48FB-419F-92A3-93D03D57E7E6Q38494659-ACDAE893-DDBA-49A2-92AE-636B4D96CFABQ38510486-DC5EEBAC-EDCA-4426-B948-F45B59E760D2Q38569175-0977DBC6-04F5-43B8-9461-761E84151B40Q38668286-0535402B-EA1E-4080-A39D-007A68BEAA2DQ38865256-EDC9490B-6F2A-40FA-9F93-FADA3F2F8BC3Q39105964-C8D3C762-8C1D-444F-9DED-F19C98F70FF4Q39116878-47A21EE0-9571-4477-B990-E6F22FE1DCE8Q39175714-5E5017EF-10E0-48AD-8E1E-472772D76991Q39674948-AECA2AAF-7823-4A82-B8C9-53F608C059EBQ41177112-23BE4D11-8788-4BCB-A76E-6DF7125DE4B1Q41463339-8F7BDB93-D394-4626-8F54-5E59ABC76E0CQ41811693-BC72451C-882B-4A9D-95C7-C502617AB014Q42324235-689F7500-8E64-47CC-942C-F5CD0661B5EFQ47558620-CF28D7CD-1107-48ED-A334-EB56DF4211C1Q47818563-F4AD8485-3257-46FE-84FE-FCFFAEA58C22Q49181559-0A25F029-934E-4E41-A9E8-43C26CF69E6DQ49338358-1B135D90-AEB6-4831-813D-8E1537D9885FQ49791801-5A44DA18-141E-46D3-B060-FEAFDAC3FCF9
P2860
FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013?
description
2013 nî lūn-bûn
@nan
2013 թուականին հրատարակուած գիտական յօդուած
@hyw
2013 թվականին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013?
@ast
FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013?
@en
FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013?
@nl
type
label
FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013?
@ast
FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013?
@en
FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013?
@nl
prefLabel
FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013?
@ast
FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013?
@en
FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013?
@nl
P2860
P3181
P1476
FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013?
@en
P2093
P2860
P3181
P356
10.1182/ASHEDUCATION-2013.1.220
P407
P577
2013-01-01T00:00:00Z